linjc16/ctgov huggingface dataset:
Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of tretinoin in treating patients who have any stage mycosis fungoides or Sezary syndrome.

Detailed Description
-----------------
OBJECTIVES: I. Determine the efficacy of tretinoin (TRA) in patients with mycosis fungoides/Sezary syndrome. II. Evaluate the spectrum of toxicity of TRA in this patient population. OUTLINE: Nonrandomized study. Single-agent Chemotherapy. Tretinoin, All-trans-Retinoic Acid, TRA, NSC-122758. PROJECTED ACCRUAL: If 1 or more of the first 15 evaluable patients experience an objective response, then 20 additional patients will be entered. It is anticipated that the accrual rate will be 1-2 patients per month.

Official Title
-----------------
Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Drug: tretinoin


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Biopsy-proven mycosis fungoides/Sezary syndrome Stage I-IV disease No CNS involvement At least 1 measurable lesion required (skin, lymph nodes, visceral lesion, or peripheral blood counts) PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-3 Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 75,000/mm3 Hepatic: Bilirubin no more than 2.0 mg/dL Transaminases no more than 2 x normal Alkaline phosphatase no more than 2 x normal Renal: Creatinine no more than 2.0 mg/dL Other: No active systemic infection No significant organ failure uncontrolled with medication No pregnant or lactating women Effective contraception required of fertile women PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior systemic therapy Chemotherapy: At least 4 weeks since prior topical chemotherapeutics or systemic therapy Endocrine therapy: At least 4 weeks since prior topical (including steroid) therapy or systemic therapy Radiotherapy: Not specified Surgery: Not specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: tretinoin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage I cutaneous T-cell non-Hodgkin lymphoma, stage II cutaneous T-cell non-Hodgkin lymphoma, stage III cutaneous T-cell non-Hodgkin lymphoma, stage IV cutaneous T-cell non-Hodgkin lymphoma
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to characterize CD86 receptor occupancy in subjects with rheumatoid arthritis (RA) receiving abatacept.

Official Title
-----------------
A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: abatacept


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject has rheumatoid arthritis (RA), is both abatacept- and belatacept-naïve, and is an eligible candidate to start a course of treatment with abatacept in accordance with the product label Subject is willing and able to comply with study visits and procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects with RA initiating abatacept treatment regimen<br>Subjects naïve to both abatacept and belatacept | Drug: abatacept<br>* Intravenous Infusion<br>* Other names: Orencia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CD86 Receptor Occupancy |  | Day 1, Weeks 2, 4, 8, and 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CD80 Receptor Occupancy |  | Day 1, Weeks 2, 4, 8, and 12 | 
| Abatacept serum concentration |  | Day 1, Weeks 2, 4, 8 and 12 | 
| Change from Day 1 to Week 12 in Subject's Global Assessment of Arthritis |  | Day 1 and Week 12 | 
| Change from Day 1 to Week 12 in Physician's Global Assessment of Arthritis |  | Day 1 and Week 12 | 
| Safety assessed by adverse event reporting including Physical Examination findings |  | Day 1 through Week 12 post-infusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Orencia, Abatacept, Rheumatoid Arthritis, Infusion
Effect of Capsular Repair on the Outcomes of Direct Anterior Total Hip Arthroplasty.

Study Overview
=================
Brief Summary
-----------------
Total hip arthroplasty is a successful surgical procedure performed as a last-line treatment in primary and secondary coxarthrosis. Recently, the direct anterior approach (DAA) has gained popularity by maintaining abduction force and reducing dislocation rates. Soft tissue stability in the anterior is increased by adding capsule repair with the preservation of the posterior structures in the DAA. The degradation of the biological structure of the capsule due to degenerative changes in the end stage coxarthrosis questions the effectiveness of the capsule repair. therefore, the effect of capsule repair on stability is still controversial.

Official Title
-----------------
Effect of Capsular Repair on the Outcomes of Direct Anterior Total Hip Arthroplasty.

Conditions
-----------------
Coxarthrosis

Intervention / Treatment
-----------------
* Procedure: Capsule repair
* Procedure: capsulectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective unilateral or bilateral primary total hip arthroplasty Direct anterior surgical approach 18 years of age or older Avascular necrosis of the hip Exclusion Criteria: Rheumatoid arthritis of the hip Revision hip arthroplasty Younger than 18 years of age Crowe type 3 and 4 coxarthrosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>Direct anterior hip arthroplasty with capsule repair. | Procedure: Capsule repair<br>* Direct anterior hip arthroplasty with or without capsule repair<br>|
| Active Comparator: Group B<br>Surgery that the surgeon will not perform capsule repair after performing an initial capsulectomy during total hip arthroplasty | Procedure: capsulectomy<br>* capsulectomy without repair<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pelvis magnetic resonance ımages(MRI) evaluation of patients who underwent direct anterior total hip arthroplasty | The new capsule mass will be evaluated by an independent radiologist. adiologist will evaluate the volume of the new capsule structure in cubic millimeter | one year |
A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies

Study Overview
=================
Brief Summary
-----------------
Peripheral neuropathies cause weakness and sensory loss that can produce severe disability. Some neuropathies are immune-mediated and associated with antibodies. It has been postulated that Rituxan treatment may reduce the level of antibody production limiting the loss of muscle strength and hence improve activities of daily living. The purpose of this open-label study (all participants get Rituxan and not placebo) is to determine the safety and effectiveness of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies in those who have already been treated with one course of Rituxan. Subjects will be treated on the in-patient Clinical Research Center with Rituxan for two treatments one week a part and then individual treatments every 10 weeks for one year. The effectiveness of Rituxan will be followed by looking for increases in muscle strength and decreases in the serum IgM autoantibodies.

Conditions
-----------------
Peripheral Neuropathy

Intervention / Treatment
-----------------
* Drug: Rituxan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of characteristic peripheral neuropathy by appropriate history, physical examination, nerve conduction findings and serum autoantibodies. Serum anti-GM1 on anti-MAG antibodies present at high titers in serum, continued by testing in the neuromuscular clinical laboratory at Washington University.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rituxan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis

Study Overview
=================
Brief Summary
-----------------
Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase. In this study the investigators try to compare the efficacy of the classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin & Dexamethasone.

Conditions
-----------------
Chorioretinitis

Intervention / Treatment
-----------------
* Drug: pyrimethamine-sulfadiazine + prednisolone
* Drug: Clindamycin+Dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Toxoplasmic chorioretinitis Location of the lesion within zone I of the retina or a lesion greater than 2DD with 3+-4+ vitreous inflammation in zone II or III No allergic history to the used drugs No any other diseases Exclusion Criteria: Any allergic reaction to the used medications One eyed patients Partially treated patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) | Drug: pyrimethamine-sulfadiazine + prednisolone<br>* Administration of pyrimethamine-sulfadiazine + prednisolone<br>|
| Active Comparator: 2<br>Intravitreal Clindamycin & Dexamethasone | Drug: Clindamycin+Dexamethasone<br>* Intravitreal injection of Clindamycin+Dexamethasone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Toxoplasmosis, Chorioretinitis, Intravitreal Clindamycin, Dexamethasone in chorioretinitis, Toxoplasmic
Training in the Workplace

Study Overview
=================
Brief Summary
-----------------
We are testing whether various cognitive training procedures can enhance cognition and brain function

Official Title
-----------------
Training in the Workplace

Conditions
-----------------
Healthy Individuals

Intervention / Treatment
-----------------
* Behavioral: Program 1
* Behavioral: Program 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy individuals aged 18-50 years old Right handed Must have reliable internet access from a desktop computer with webcam English speaking Exclusion Criteria: Neurological conditions pregnancy metalic implants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Program 1<br>Program 1 | Behavioral: Program 1<br> <br> |
| Active Comparator: Program 2<br>Program 2 | Behavioral: Program 2<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI | Functional and structural MR images will be acquired | 2 hours Pre and Post intervention |
Non - Invasive Evaluation of the Left Atrium Anatomy and Function

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the accuracy and reproducibility of the left atrium (LA) anatomy and function in different populations and in patients with atrial fibrillation who have undergone cryoballoon ablation.

Detailed Description
-----------------
This study implies three parts. The first part of the study aims to evaluate the variability and reproducibility of rest two - and three-dimensional echocardiography for the left atrium anatomy and function and to assess their correlation with clinical variables. The second part of the study aims to evaluate the accuracy and reproducibility of the left atrium anatomy and function using echocardiography and to validate it with cardiac CT. Moreover, the study aims to evaluate which parameters can predict the recurrence of atrial fibrillation in patients who have undergone atrial fibrillation ablation. The third part of the study aims to assess the accuracy and variability of echocardiographic measurements compared to cardiac magnetic resonance and to find predictors of recurrence after cryoballoon ablation for atrial fibrillation.

Official Title
-----------------
The Search for Non-invasive Determinants of Response to Ablation of Atrial Fibrillation. Non-invasive Evaluation of Left Atrium Anatomy and Function With Three Dimensional Echocardiography: Comparison With Cardiac CT and MRI

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Diagnostic Test: Echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subsequent group of patients sent to the echocardiography laboratory for any indication/patients who have undergone a cryoballoon ablation older than 18 years old Exclusion Criteria: • inadequate image quality during echocardiography, contraindications for computed tomography or cardiac magnetic resonance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Atrial fibrillation patients<br>Patients with atrial fibrillation who underwent cryoballoon ablation | Diagnostic Test: Echocardiography<br>* Cardiac imaging for the assessment of the left atrium anatomy and function.<br>* Other names: cardiac magnetic resonance;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Atrial fibrillation recurrence | Predictors of atrial fibrillation recurrence after ablation | 1 year |
Autologous Platelets Rich Plasma (APRP) Treatment Vs Saline Dressing for the Management of Diabetic Foot Ulcer

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare between the platelet rich plasma and normal saline dressing in the healing diabetic foot ulcers. It will be a randomized controlled trial.

Official Title
-----------------
Autologous Platelets Rich Plasma (APRP) Treatment Vs Saline Dressing for the Management of Diabetic Foot Ulcer

Conditions
-----------------
Diabetic Foot Ulcer

Intervention / Treatment
-----------------
* Other: Autologous Platelets Rich Plasma Treatment
* Other: Conventional Saline dressing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic foot wound less than 5cm in greatest diameter Non healing duration greater than 3 months Non infected Palpable distal pulses Exclusion Criteria: Infected wound Wound greater than 5 cm Patient having HBa1c greater than 8% Renal failure Wound with bone exposed or having osteomyelitis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Autologous Platelets Rich Plasma<br>In this group we will be managing diabetic wounds with platelet rich plasma treatment. | Other: Autologous Platelets Rich Plasma Treatment<br>* For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.<br>|
| Active Comparator: Conventional Saline dressing<br>In this group we will be managing diabetic wounds with normal saline dressing. | Other: Conventional Saline dressing<br>* saline dressing of diabetic wounds will be done<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wound Healing | complete healing of diabetic foot | 8 to 12 weeks |
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if giving 1592U89 to HIV-infected patients is safe and effective in lowering viral load (level of HIV in the blood) and raising the level of CD4 cells (cells of the body that help fight infection).

Detailed Description
-----------------
Patients are randomized to receive one of three doses of 1592U89. During this randomized dosing phase, if a patient meets one of the following criteria, he/she is offered open-label 1592U89 (300 mg) plus zidovudine (ZDV) plus lamivudine (3TC) (or other licensed antiretrovirals according to standard practice). Criteria are based on falling CD4 counts (return to baseline on two occasions at least 1 month apart), disease progression (defined as occurrence of a new AIDS-defining event according to CDC classification excluding CD4 counts less than 200 cells/mm3), or lack of virus suppression (defined as less than 0.7log10 reduction in viral load at Week 4 with a repeat value 1 week later, more than 5000 copies/ml HIV RNA at Weeks 12, 16, 20, or 24, or 5000 copies/ml or more anytime after Week 24).

Official Title
-----------------
A Phase II Randomized, Blinded, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Different Regimens of 1592U89 Monotherapy Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy-Naive Patients

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Abacavir sulfate


Participation Criteria
=================

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Abacavir sulfate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |